贊宇科技(002637.SZ):擬在廣東投資建設年產25萬噸綠色表面活性劑項目
格隆匯6月12日丨贊宇科技(002637.SZ)公告,公司為滿足華南地區的市場供需,鞏固表面活性劑在華南地區的市場佔有率,繼續積極拓展新興市場,擬在廣東投資建設年產25萬噸綠色表面活性劑項目。
2020年6月12日,公司與江門市新會區工業園區管理委員會在江門市簽署《贊宇科技綠色表面活性劑項目投資合作協議書》,選址廣東省江門市新會區珠西新材料集聚區設立全資子公司“廣東贊宇科技有限公司”(以下簡稱“廣東贊宇”,暫定名,以工商部門核准為準),並投資建設年產25萬噸的綠色表面活性劑項目,由廣東贊宇負責項目的具體運作。項目總投資約4.3億元。資金來源為公司自有資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.